Skip to main content

Advertisement

SpringerLink
Log in

Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer

  • Invited Commentary
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

The Original Article was published on 02 April 2010

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Smith I (2006) Goals of treatment for patients with metastatic breast cancer. Semin Oncol 33(1 Suppl 2):S2–S5

    Article  PubMed  Google Scholar 

  2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792

    Article  CAS  PubMed  Google Scholar 

  3. O’Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Monaghan G, et al (2009) Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol 27(18 Suppl):(abstr 3)

  4. O’Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20(12):2812–2823

    Article  PubMed  CAS  Google Scholar 

  5. Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A et al (2008) Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 26(24):3950–3957

    Article  PubMed  Google Scholar 

  6. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK et al (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21(4):588–592

    Article  PubMed  Google Scholar 

  7. Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF et al (2007) Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25(33):5210–5217

    Article  CAS  PubMed  Google Scholar 

  8. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666–2676

    Article  CAS  PubMed  Google Scholar 

  9. Sanchez-Munoz A, Perez-Ruiz E, Ribelles N, Marquez A, Alba E (2008) Maintenance treatment in metastatic breast cancer. Expert Rev Anticancer Ther 8(12):1907–1912

    Article  CAS  PubMed  Google Scholar 

  10. Ejlertsen B, Pfeiffer P, Pedersen D, Mouridsen HT, Rose C, Overgaard M et al (1993) Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. Eur J Cancer 29A(4):527–531

    Article  CAS  PubMed  Google Scholar 

  11. Gennari A, Sormani M, Bruzzi P, Wilcken N, Nanni O, Fornier M, et al (2008) A meta-analysis of chemotherapy duration in metastatic breast cancer (MBC). J Clin Oncol 26(May 20 Suppl):abstr 1067

  12. Coates A, Gebski V, Bishop JF, Jeal PN, Woods RL, Snyder R et al (1987) Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 317(24):1490–1495

    Article  CAS  PubMed  Google Scholar 

  13. Nooij MA, de Haes JC, Beex LV, Wildiers J, Klijn J, Becquart D et al (2003) Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. Clinical outcomes and oncologists’ preferences. Eur J Cancer 39(5):614–621

    Article  CAS  PubMed  Google Scholar 

  14. Alba E, Ruiz-Borrego M, Margeli M, Rodriguez-Lescure A, Sanchez-Rovira P, Ruiz A, et al. Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. Breast Cancer Res Treat. doi:10.1007/s10549-010-0860-9

  15. Alba E, Martin M, Ramos M, Adrover E, Balil A, Jara C et al (2004) Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) Phase III Study. J Clin Oncol 22(13):2587–2593

    Article  CAS  PubMed  Google Scholar 

  16. Gennari A, Amadori D, De Lena M, Nanni O, Bruzzi P, Lorusso V et al (2006) Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol 24(24):3912–3918

    Article  CAS  PubMed  Google Scholar 

  17. Mayordomo J, Baena J, Cirera L, Sanchez-Rovira P, Godes M, Galan A et al (2009) Final results of a randomized trial on the role of maintenance chemotherapy with weekly paclitaxel for patients with metastatic breast cancer. J Clin Oncol 27(15 suppl) (abstr 1001)

  18. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E et al (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374(9699):1432–1440

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Memorial Sloan-Kettering Cancer Center, 300 E66th Street, New York, NY, 10065, USA

    C. G. Murphy, M. Khasraw & A. D. Seidman

Authors
  1. C. G. Murphy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Khasraw
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. D. Seidman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. D. Seidman.

Additional information

This is an invited commentary to article doi: 10.1007/s10549-010-0860-9.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Murphy, C.G., Khasraw, M. & Seidman, A.D. Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer. Breast Cancer Res Treat 122, 177–179 (2010). https://doi.org/10.1007/s10549-010-0925-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-010-0925-9

Keywords

Search

Navigation